Drugs / 12-Valent Pneumococcal Conjugate Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05721456 | Aug 2023 → Apr 2024 | — | Maria de Lourdes de Sousa Maia, MD | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 12-Valent Pneumococcal Conjugate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05721456 ↗ |
| Known as | 12Pn-PD-DiT-CRM | “12-valent pneumococcal polysaccharide conjugate vaccine (12Pn-PD-DiT-CRM, hereby indicated as PCV12)” NCT05721456 ↗ |
| Modality | Vaccine | “12-valent pneumococcal polysaccharide conjugate vaccine” NCT05721456 ↗ |